PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 28, 2026Journal of Drug Research in Ayurvedic Sciences0 citationsOpen Access

A survey for labeling compliance of Ayurvedic medicines containing Schedule E1 drugs mentioned in the Drugs and Cosmetics Act

View Full Paper
RCRajan ChauhanRKRasika KolheRARabinarayan Acharya

Key Points

  • This research aims to assess the labeling compliance of Ayurvedic medicines that include Schedule E1 substances, ensuring adherence to regulatory standards.
  • Collected labels from 26 Ayurvedic retailers/pharma companies based on convenience sampling.
  • Evaluated against a checklist of quality criteria outlined in the Drugs and Cosmetics Act.
  • Quantified compliance rates as percentages.
  • 372 Ayurvedic classical formulations contain Schedule E1 drugs according to the Ayurvedic Formulary of India.
  • Among 318 observed labels, 14% of classical formulations lacked required ingredient information.
  • 11% of classical and 45% of proprietary formulations missed caution warnings for Schedule E1 contents.

Abstract

Abstract BACKGROUND: Poisonous substances under the Ayurvedic System of Medicine are listed in Schedule E1 of the Drugs and Cosmetics Act (D and C Act), 1940, and Rules, 1945, which mandates caution in their use. Furthermore, Part XVII, Rule 161 of the act specifies labeling requirements for Ayurvedic drugs, ensuring consumer safety and regulatory compliance. In this context, the present study was undertaken to evaluate the labeling information provided on containers of Ayurvedic drugs containing Schedule E1 substances and to examine the extent of compliance with the provisions of the D and C Act, 1940. METHODS: Labels of Ayurvedic classical, as well as Ayurvedic proprietary medicines, containing an ingredient of Schedule E1, were collected from the 26 Ayurvedic retailers/pharma companies based on the convenience sampling method. Their contents were checked against a checklist of quality criteria given in the act. The results are expressed as percentages. RESULTS: A literature review of the Ayurvedic Formulary of India showed that a total of 372 Ayurvedic classical formulations are reported as any of the ingredients of Schedule E1 drugs. In this study, a total of 318 labels were observed, comprising 161 (51%) classical formulations and 157 (49%) proprietary formulations. In the classical formulation, 14% of labels did not comply with a list of ingredients, botanical name, and quantity of each ingredient. A caution warning for schedule E1 drug-containing medicines was missing on 11% of classical as well as 45% proprietary medicines. CONCLUSION: This study provides scientific information on the labeling of Schedule E (1) containing drugs, and the data obtained may prove helpful for policy decisions towards improving patient safety and labeling of Ayurvedic drugs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chauhan et al. (2026) studied this question.

synapsesocial.com/papers/69a286370a974eb0d3c00fd2https://doi.org/10.4103/jdras.jdras_82_22
Ask AI
Helpful
Bookmark
Share
View Full Paper